Femasys Inc. (FEMY)
NASDAQ: FEMY · Real-Time Price · USD
0.520
-0.008 (-1.52%)
Mar 6, 2026, 4:00 PM EST - Market closed
Femasys Employees
As of December 31, 2024, Femasys had 71 total employees, including 69 full-time and 2 part-time employees. The number of employees increased by 37 or 108.82% compared to the previous year.
Employees
71
Change (1Y)
37
Growth (1Y)
108.82%
Revenue / Employee
$29,035
Profits / Employee
-$278,891
Market Cap
30.88M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Harvard Bioscience | 355 |
| Jin Medical International | 273 |
| Retractable Technologies | 227 |
| Bionano Genomics | 100 |
| Precision Optics Corporation | 90 |
| Ekso Bionics Holdings | 55 |
| Sharps Technology | 55 |
| Nephros | 31 |
FEMY News
- 6 days ago - Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 11 days ago - Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination - GlobeNewsWire
- 7 weeks ago - Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care - GlobeNewsWire
- 2 months ago - Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device - GlobeNewsWire
- 3 months ago - PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment - Business Wire
- 4 months ago - Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million - GlobeNewsWire
- 5 months ago - Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo - GlobeNewsWire
- 6 months ago - Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed® - GlobeNewsWire